Talking the talk

'Troxacitabine - that's a word that I just can't seem to say right,' confesses Peter McBride, the vice president of communications and investor relations for Montreal-based BioChem Pharma. There's an slight undertone of humor in his voice, as if he's sharing a rather embarrassing confidence.'That's a shame, because Troxaci - whatever - is one of our products in development,' McBride says. 'I still can't pronounce all these terms. I really have to master them.'All joking aside, McBride is quick